PURPOSE: To elucidate the efficiency of contrast-enhanced ultrasonography alone and in combination with other noninvasive models for grading hepatic fibrosis. METHODS: This prospective study included 74 patients with four grades (F1-F4) of chronic liver disease (17, 20, 18, and 19 patients, respectively). Diagnostic performances of the contrast parameter (time to the maximum intensity ratio between the right portal vein and liver parenchyma from the onset of contrast enhancement in the right portal vein) assessed by ultrasonography, liver stiffness measurement (LSM), FIB-4 test, and type IV collagen 7s were compared with histological findings. RESULTS: Greatest areas under the receiver operating characteristics curve (Az) with the single model were 0.83 (95 % confidence interval 0.71-0.91) for marked fibrosis (≥F2) by FIB-4 test; 0.85 (0.73-0.92) for advanced fibrosis (≥F3) by LSM, and 0.92 (0.83-0.96) by type IV collagen 7s for cirrhosis (F4). When combined, Az for marked fibrosis was ≥0.82; the best Az value was 0.87 (0.74-0.94) for the combination of contrast parameter with FIB-4. Similarly, the Az for advanced fibrosis was ≥0.82, and the best Az value was 0.89 (0.78-0.94) for the combination of contrast parameter with LSM. The Az for cirrhosis was ≥0.95, and the best Az was 0.99 (0.97-1.00) for the combination of contrast parameter with LSM. CONCLUSIONS: The contrast parameter is a promising predictor for grading hepatic fibrosis when combined with LSM or FIB-4.
PURPOSE: To elucidate the efficiency of contrast-enhanced ultrasonography alone and in combination with other noninvasive models for grading hepatic fibrosis. METHODS: This prospective study included 74 patients with four grades (F1-F4) of chronic liver disease (17, 20, 18, and 19 patients, respectively). Diagnostic performances of the contrast parameter (time to the maximum intensity ratio between the right portal vein and liver parenchyma from the onset of contrast enhancement in the right portal vein) assessed by ultrasonography, liver stiffness measurement (LSM), FIB-4 test, and type IV collagen 7s were compared with histological findings. RESULTS: Greatest areas under the receiver operating characteristics curve (Az) with the single model were 0.83 (95 % confidence interval 0.71-0.91) for marked fibrosis (≥F2) by FIB-4 test; 0.85 (0.73-0.92) for advanced fibrosis (≥F3) by LSM, and 0.92 (0.83-0.96) by type IV collagen 7s for cirrhosis (F4). When combined, Az for marked fibrosis was ≥0.82; the best Az value was 0.87 (0.74-0.94) for the combination of contrast parameter with FIB-4. Similarly, the Az for advanced fibrosis was ≥0.82, and the best Az value was 0.89 (0.78-0.94) for the combination of contrast parameter with LSM. The Az for cirrhosis was ≥0.95, and the best Az was 0.99 (0.97-1.00) for the combination of contrast parameter with LSM. CONCLUSIONS: The contrast parameter is a promising predictor for grading hepatic fibrosis when combined with LSM or FIB-4.
Entities:
Keywords:
Cirrhosis; FIB-4; Fibrosis; Liver stiffness; Type IV collagen 7s; Ultrasonography
Authors: Anna S F Lok; Marc G Ghany; Zachary D Goodman; Elizabeth C Wright; Gregory T Everson; Richard K Sterling; James E Everhart; Karen L Lindsay; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Timothy R Morgan; Jules L Dienstag; Chihiro Morishima Journal: Hepatology Date: 2005-08 Impact factor: 17.425
Authors: M J K Blomley; A K P Lim; C J Harvey; N Patel; R J Eckersley; R Basilico; R Heckemann; A Urbank; D O Cosgrove; S D Taylor-Robinson Journal: Gut Date: 2003-08 Impact factor: 23.059
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Robert J Fontana; Zachary D Goodman; Jules L Dienstag; Herbert L Bonkovsky; Deepa Naishadham; Richard K Sterling; Grace L Su; Mita Ghosh; Elizabeth C Wright Journal: Hepatology Date: 2008-03 Impact factor: 17.425
Authors: F Staub; C Tournoux-Facon; J Roumy; C Chaigneau; M Morichaut-Beauchant; P Levillain; C Prevost; C Aubé; J Lebigot; F Oberti; J B Galtier; H Laumonier; H Trillaud; P H Bernard; J F Blanc; S Sironneau; F Machet; J Drouillard; V de Ledinghen; P Couzigou; P Foucher; L Castéra; F Tranquard; Y Bacq; L d'Altéroche; P Ingrand; J P Tasu Journal: Eur Radiol Date: 2009-03-04 Impact factor: 5.315